Pharmacokinetics and Initial Bolus Dosing of Furosemide in Children on ECMO

Extracorporeal membrane oxygenation (ECMO) is an established technology that provides life-saving mechanical support for critically ill children. In these children, fluid overload is commonly treated with furosemide; however, optimal dosing of furosemide is unknown in children supported with ECMO because ECMO may alter furosemide exposure. In this work, human blood-primed ex vivo experiments quantified red blood cell partitioning and extraction of furosemide by the ECMO circuit. Furosemide partitioned into red blood cells but was not extracted by ECMO circuits. These data then parameterized a pediatric physiologically based pharmacokinetic (PBPK) model of furosemide in children with and without ECMO. Next, plasma furosemide concentrations from 10 critically ill children supported by ECMO were used to evaluate PBPK model performance, with the optimized model achieving average fold error and absolute average fold error of 1.02 and 1.67, respectively. The optimized PBPK model also predicted that ECMO increases apparent volume of distribution by a median of > 30% in neonates and infants. Finally, population PBPK simulations with the optimized PBPK model provided initial bolus doses that most rapidly achieve steady-state plasma furosemide concentrations with and without ECMO. These calibrated initial bolus doses achieved steady-state plasma furosemide concentrations > 3 h faster than continuous infusions without an initial bolus dose, and this improvement was most pronounced in neonates and infants on ECMO. Overall, this work supports comparatively larger initial bolus doses for neonates and infants on ECMO, and provides calibrated initial bolus doses based on plasma exposure for critically ill children.

Authors

Institutions

Publication Details

Journal
CPT Pharmacometrics & Systems Pharmacology
Published
2026-11-18
DOI
https://doi.org/10.1002/psp4.70370
Primary Topic
Pharmaceutical studies and practices
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pharmacokinetics and Initial Bolus Dosing of Furosemide in Children on ECMO

Andrew Chevalier, Aviva Whelan, David J. Anderson, Kevin Watt et al.
CPT Pharmacometrics & Systems Pharmacology
Pharmaceutical studies and practices
article

Pharmacokinetics and Initial Bolus Dosing of Furosemide in Children on ECMO

Andrew Chevalier, Aviva Whelan, David J. Anderson, Kevin Watt, John Porter Hunt, Autumn M. McKnite, Ariel Tarrell, Danielle J. Green, Gideon A. Stitt, Joseph E. Rower, Carina E. Imburgia
article en

Abstract

Extracorporeal membrane oxygenation (ECMO) is an established technology that provides life-saving mechanical support for critically ill children. In these children, fluid overload is commonly treated with furosemide; however, optimal dosing of furosemide is unknown in children supported with ECMO because ECMO may alter furosemide exposure. In this work, human blood-primed ex vivo experiments quantified red blood cell partitioning and extraction of furosemide by the ECMO circuit. Furosemide partitioned into red blood cells but was not extracted by ECMO circuits. These data then parameterized a pediatric physiologically based pharmacokinetic (PBPK) model of furosemide in children with and without ECMO. Next, plasma furosemide concentrations from 10 critically ill children supported by ECMO were used to evaluate PBPK model performance, with the optimized model achieving average fold error and absolute average fold error of 1.02 and 1.67, respectively. The optimized PBPK model also predicted that ECMO increases apparent volume of distribution by a median of > 30% in neonates and infants. Finally, population PBPK simulations with the optimized PBPK model provided initial bolus doses that most rapidly achieve steady-state plasma furosemide concentrations with and without ECMO. These calibrated initial bolus doses achieved steady-state plasma furosemide concentrations > 3 h faster than continuous infusions without an initial bolus dose, and this improvement was most pronounced in neonates and infants on ECMO. Overall, this work supports comparatively larger initial bolus doses for neonates and infants on ECMO, and provides calibrated initial bolus doses based on plasma exposure for critically ill children.

CPT Pharmacometrics & Systems PharmacologyVol. 15(12)
University of Utah (US)
American Foundation for Pharmaceutical Education, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Child Health and Human Development, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Good health and well-being
Pharmaceutical studies and practices
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon